In this podcast, Dr Seth Baum interviews Dr Mikhail Kosiborod about clinical trial data surrounding the possible mechanisms of action of SLGT2 inhibitors for heart failure, as well as the cardio-renal connection.
Seth Baum, MD, is president of the American Society for Preventive Cardiology (ASPC), clinical affiliate professor at the Schmidt College of Medicine at Florida Atlantic University, and CEO of Excel Medical Clinical Trials in Boca Raton, Florida.
Mikhail N. Kosiborod, MD, is a cardiologist at Saint Luke's Cardiovascular Consultants in Lees Summit, Missouri; professor of medicine at the University of Missouri; and researcher in HFrEF and HFpEF.
For more content related to heart failure, visit Heart Failure Care360.
Published in partnership with 